U.S. markets open in 3 hours 34 minutes
  • S&P Futures

    3,622.25
    -38.75 (-1.06%)
     
  • Dow Futures

    28,958.00
    -245.00 (-0.84%)
     
  • Nasdaq Futures

    11,168.25
    -165.50 (-1.46%)
     
  • Russell 2000 Futures

    1,653.00
    -15.40 (-0.92%)
     
  • Crude Oil

    78.19
    -0.31 (-0.39%)
     
  • Gold

    1,626.00
    -10.20 (-0.62%)
     
  • Silver

    18.00
    -0.34 (-1.84%)
     
  • EUR/USD

    0.9553
    -0.0045 (-0.47%)
     
  • 10-Yr Bond

    3.9640
    0.0000 (0.00%)
     
  • Vix

    34.61
    +2.35 (+7.28%)
     
  • GBP/USD

    1.0683
    -0.0048 (-0.45%)
     
  • USD/JPY

    144.7390
    -0.0520 (-0.04%)
     
  • BTC-USD

    18,646.46
    -1,528.40 (-7.58%)
     
  • CMC Crypto 200

    426.60
    -32.54 (-7.09%)
     
  • FTSE 100

    6,861.31
    -123.28 (-1.77%)
     
  • Nikkei 225

    26,173.98
    -397.89 (-1.50%)
     

Clinuvel Pharmaceuticals' (ASX:CUV) earnings growth rate lags the 25% CAGR delivered to shareholders

·3 min read

It's been a soft week for Clinuvel Pharmaceuticals Limited (ASX:CUV) shares, which are down 14%. But that scarcely detracts from the really solid long term returns generated by the company over five years. We think most investors would be happy with the 206% return, over that period. We think it's more important to dwell on the long term returns than the short term returns. The more important question is whether the stock is too cheap or too expensive today. Unfortunately not all shareholders will have held it for the long term, so spare a thought for those caught in the 50% decline over the last twelve months.

While this past week has detracted from the company's five-year return, let's look at the recent trends of the underlying business and see if the gains have been in alignment.

See our latest analysis for Clinuvel Pharmaceuticals

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

During five years of share price growth, Clinuvel Pharmaceuticals achieved compound earnings per share (EPS) growth of 23% per year. This EPS growth is reasonably close to the 25% average annual increase in the share price. This indicates that investor sentiment towards the company has not changed a great deal. Rather, the share price has approximately tracked EPS growth.

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

earnings-per-share-growth
earnings-per-share-growth

It might be well worthwhile taking a look at our free report on Clinuvel Pharmaceuticals' earnings, revenue and cash flow.

A Different Perspective

We regret to report that Clinuvel Pharmaceuticals shareholders are down 50% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 4.5%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Longer term investors wouldn't be so upset, since they would have made 25%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Clinuvel Pharmaceuticals better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Clinuvel Pharmaceuticals , and understanding them should be part of your investment process.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here